A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer

A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer

Medullary thyroid cancer (MTC) accounts for ~4% of all thyroid malignancies. MTC derives from the neural crest and secretes calcitonin (CTN) and carcinoembryonic antigen (CEA). Unlike differentiated thyroid cancer, MTC does not uptake iodine and I-131 RAI (radioactive iodine) treatment is ineffectiv...

Full description

Bibliographic Details
Main Authors: Jaydira Del Rivero, Renee N. Donahue, Jennifer L. Marté, Ann W. Gramza, Marijo Bilusic, Myrna Rauckhorst, Lisa Cordes, Maria J. Merino, William L. Dahut, Jeffrey Schlom, James L. Gulley, Ravi A. Madan
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-08-01
Series:Frontiers in Endocrinology
Subjects:
medullary thyroid cancer
CEA
calcitonin
immunotherapy
PD-L1 inhibitor
Online Access:https://www.frontiersin.org/article/10.3389/fendo.2020.00490/full

Internet

https://www.frontiersin.org/article/10.3389/fendo.2020.00490/full

Similar Items